HSP90AA1 and plasma cell myeloma: Surprisingly, HSP90 has never been tested with cytokine-induced killer (CIK) cell therapy, which has recently turned 30 years old and has been shown to be successful across various hematological malignancies, including B-cell malignancies [47], multiple myeloma [48], and acute myeloid leukemia [49].